Page 416 - 2014 Printable Abstract Book
P. 416
2;1
1
(PS7-66) Creation of a biobank of a french haemangioma cohort. Monika Frenzel ; Marion Bellamy ;
1
2
1
Aude Lenain ; Florent de Vathaire ; and Laure Sabatier CEA - Fontenay aux Roses, Fontenay aux Roses,
1
France and Centre de Recherches en Epidémiologie et Santé des Populations, Equipe 3, UMR1018,
2
Inserm, Paris, France
The establishment of a biobank is a complex and often underestimated, time-consuming process.
Within the project EpiRadBio – financed by the European Union – a biobank of blood samples of a French
haemangioma cohort (FHC) is created. In contrast to common biobanks this FHC biobank is not consisting
of frozen or paraffin embedded tissue or simple blood samples frozen directly after sampling but of
isolated nucleated blood cells preserved in liquid nitrogen under conditions (10% DMSO in serum)
allowing not only all kinds of DNA/RNA or FACS analysis but also a later on cell culture. Additionally,
cytogenetic slides of B- and T-lymphocytes are available. Between 1940 and 1973 in France, some
members of this cohort have been treated for their haemangioma during their early childhood with
32
90
226
90
radiotherapy ( Ra, X-rays, P, Y or Sr) until this type of therapy was forbidden due to the sensitization
for the negative side effects of ionizing radiation. Epidemiological analysis of this cohort demonstrated a
three times higher risk of getting cancer (especially skin, breast and thyroid cancer). All treated patients
belonging to the biobank of the FHC have been irradiated before the age of three with sometimes high
local doses at the haemangioma but low doses at the bone marrow site – the place of blood cell
production. Additionally, the cohort contains non-exposed people (with or without cryotherapy) serving
as controls. Therefore, the FHC gives the remarkable opportunity to study a highly homogeneous group
of patients characterized by having a haemangioma during childhood but no other pathologies than a
normal population. It might help to reveal why the treatment of a haemangioma during childhood is
leading to higher cancer risk at organs that received only very low doses. The challenge of establishing a
human sample biobank especially of principally healthy donors (not even knowing in some cases that they
have been irradiated during infancy) is to get all necessary authorizations for contacting the donors and
to collect the samples. After this hurdle is taken (two years duration for the FHC) the donors can be
contacted to inform them about the study and to ask for their contribution. In the case of acceptance,
they have to sign a declaration of consent and samples can be taken afterwards. The advantage of the
FHC is that a constant follow-up exists. The place of residence – necessary information to contact the
donors – was actualized for the majority of the cases and volunteers within the cohort already
contributing at recent epidemiology studies are present. Besides the biological samples forming the
biobank this cohort will be characterized by detailed information of every patient: medical follow-up as
well as individual confounding factors (provided by questionnaires). This biobank is far from being static,
since the donors are still alive (between the ages of 41-74 now) and only a small percentage of available
people have been yet included. Within EpiRadBio we will perform an exposed/non-exposed study to
reveal the effect of low dose ionizing radiation at the bone marrow site on the telomere length of
lymphocyte after radiation treatment for a haemangioma during infancy.
1
(PS7-66) Creation of a biobank of a french haemangioma cohort. Monika Frenzel ; Marion Bellamy ;
1
2
1
Aude Lenain ; Florent de Vathaire ; and Laure Sabatier CEA - Fontenay aux Roses, Fontenay aux Roses,
1
France and Centre de Recherches en Epidémiologie et Santé des Populations, Equipe 3, UMR1018,
2
Inserm, Paris, France
The establishment of a biobank is a complex and often underestimated, time-consuming process.
Within the project EpiRadBio – financed by the European Union – a biobank of blood samples of a French
haemangioma cohort (FHC) is created. In contrast to common biobanks this FHC biobank is not consisting
of frozen or paraffin embedded tissue or simple blood samples frozen directly after sampling but of
isolated nucleated blood cells preserved in liquid nitrogen under conditions (10% DMSO in serum)
allowing not only all kinds of DNA/RNA or FACS analysis but also a later on cell culture. Additionally,
cytogenetic slides of B- and T-lymphocytes are available. Between 1940 and 1973 in France, some
members of this cohort have been treated for their haemangioma during their early childhood with
32
90
226
90
radiotherapy ( Ra, X-rays, P, Y or Sr) until this type of therapy was forbidden due to the sensitization
for the negative side effects of ionizing radiation. Epidemiological analysis of this cohort demonstrated a
three times higher risk of getting cancer (especially skin, breast and thyroid cancer). All treated patients
belonging to the biobank of the FHC have been irradiated before the age of three with sometimes high
local doses at the haemangioma but low doses at the bone marrow site – the place of blood cell
production. Additionally, the cohort contains non-exposed people (with or without cryotherapy) serving
as controls. Therefore, the FHC gives the remarkable opportunity to study a highly homogeneous group
of patients characterized by having a haemangioma during childhood but no other pathologies than a
normal population. It might help to reveal why the treatment of a haemangioma during childhood is
leading to higher cancer risk at organs that received only very low doses. The challenge of establishing a
human sample biobank especially of principally healthy donors (not even knowing in some cases that they
have been irradiated during infancy) is to get all necessary authorizations for contacting the donors and
to collect the samples. After this hurdle is taken (two years duration for the FHC) the donors can be
contacted to inform them about the study and to ask for their contribution. In the case of acceptance,
they have to sign a declaration of consent and samples can be taken afterwards. The advantage of the
FHC is that a constant follow-up exists. The place of residence – necessary information to contact the
donors – was actualized for the majority of the cases and volunteers within the cohort already
contributing at recent epidemiology studies are present. Besides the biological samples forming the
biobank this cohort will be characterized by detailed information of every patient: medical follow-up as
well as individual confounding factors (provided by questionnaires). This biobank is far from being static,
since the donors are still alive (between the ages of 41-74 now) and only a small percentage of available
people have been yet included. Within EpiRadBio we will perform an exposed/non-exposed study to
reveal the effect of low dose ionizing radiation at the bone marrow site on the telomere length of
lymphocyte after radiation treatment for a haemangioma during infancy.
